Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Establishing the Socio-Economic Impact of Degenerative Cervical Myelopathy Is Fundamental to Improving Outcomes [Ao Spine Recode-Dcm Research Priority Number 8] Publisher



Davies BM1, 2 ; Phillips R3 ; Clarke D1 ; Furlan JC4, 5 ; Demetriades AK6 ; Milligan J7 ; Witiw CD8 ; Harrop JS9 ; Aarabi B10 ; Kurpad SN11 ; Guest JD12 ; Wilson JR8 ; Kwon BK13 ; Vaccaro AR14 Show All Authors
Authors
  1. Davies BM1, 2
  2. Phillips R3
  3. Clarke D1
  4. Furlan JC4, 5
  5. Demetriades AK6
  6. Milligan J7
  7. Witiw CD8
  8. Harrop JS9
  9. Aarabi B10
  10. Kurpad SN11
  11. Guest JD12
  12. Wilson JR8
  13. Kwon BK13
  14. Vaccaro AR14
  15. Fehlings MG8
  16. Rahimimovaghar V15
  17. Kotter MRN1, 2

Source: Global Spine Journal Published:2022


Abstract

Study Design: Literature Review (Narrative). Objective: To contextualize AO Spine RECODE-DCM research priority number 5: What is the socio-economic impact of DCM? (The financial impact of living with DCM to the individual, their supporters, and society as a whole). Methods: In this review, we introduce the methodology of health-economic investigation, including potential techniques and approaches. We summarize the current health-economic evidence within DCM, so far focused on surgical treatment. We also cover the first national estimate, in partnership with Myelopathy.org from the United Kingdom, of the cost of DCM to society. We then demonstrate the significance of this question to advancing care and outcomes in the field. Results: DCM is a common and often disabling condition, with a significant lack of recognition. While evidence demonstrates the cost-effectives of surgery, even among higher income countries, health inequalities exist. Further the prevalent residual disability in myelopathy, despite treatment affects both the individual and society as a whole. A report from the United Kingdom provides the first cost-estimate to their society; an annual cost of ∼£681.6 million per year, but this is likely a significant underestimate. Conclusion: A clear quantification of the impact of DCM is needed to raise the profile of a common and disabling condition. Current evidence suggests this is likely to be globally substantial. © The Author(s) 2022.
Other Related Docs